

Yasir Waheed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5166920/publications.pdf>

Version: 2024-02-01

133
papers

60,588
citations

50273

46
h-index

12944

131
g-index

139
all docs

139
docs citations

139
times ranked

66829
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	13.7	8,569
2	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	13.7	7,664
3	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	13.7	4,989
4	Global Burden of Cardiovascular Diseases and Risk Factors, 1990â€“2019. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2982-3021.	2.8	4,468
5	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	13.7	3,928
6	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	13.7	3,269
7	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2020, 395, 709-733.	13.7	2,858
8	Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 459-480.	10.2	2,625
9	Global, regional, and national burden of stroke and its risk factors, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Neurology, The</i> , 2021, 20, 795-820.	10.2	2,308
10	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	13.7	2,123
11	Alcohol use and burden for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035.	13.7	2,005
12	Global, regional, and national burden of stroke, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 439-458.	10.2	2,005
13	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	7.1	1,691
14	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	8.1	1,241
15	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 56-87.	10.2	1,064
16	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€“2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	13.7	890
17	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 245-266.	8.1	823
18	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	13.7	716

#	ARTICLE	IF	CITATIONS
19	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	13.7	638
20	Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990â€“2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2021, 397, 2337-2360.	13.7	609
21	Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. <i>BMJ: British Medical Journal</i> , 2019, 364, l94.	2.3	558
22	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV,the</i> , 2019, 6, e831-e859.	4.7	341
23	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	13.7	335
24	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	13.7	335
25	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1250-1284.	13.7	330
26	Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. <i>Lancet Respiratory Medicine,the</i> , 2019, 7, 69-89.	10.7	326
27	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	13.7	294
28	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2021, 398, 870-905.	13.7	229
29	Global, regional, and national burden of meningitis, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2018, 17, 1061-1082.	10.2	221
30	The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Oncology, The</i> , 2019, 20, 1211-1225.	10.7	199
31	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , 2019, 574, 353-358.	27.8	161
32	Hepatitis C virus in Pakistan: A systematic review of prevalence, genotypes and risk factors. <i>World Journal of Gastroenterology</i> , 2009, 15, 5647.	3.3	148
33	Mapping child growth failure across low- and middle-income countries. <i>Nature</i> , 2020, 577, 231-234.	27.8	128
34	Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 37-59.	9.1	104
35	Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i96-i114.	2.4	103
36	Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 60-79.	9.1	95

#	ARTICLE	IF	CITATIONS
37	Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. <i>Lancet, The</i> , 2021, 398, 503-521.	13.7	93
38	Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2021, 398, 1593-1618.	13.7	92
39	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. <i>The Lancet Global Health</i> , 2020, 8, e1162-e1185.	6.3	91
40	Hepatitis elimination by 2030: Progress and challenges. <i>World Journal of Gastroenterology</i> , 2018, 24, 4959-4961.	3.3	80
41	Mapping subnational HIV mortality in six Latin American countries with incomplete vital registration systems. <i>BMC Medicine</i> , 2021, 19, 4.	5.5	78
42	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2020, 395, 1779-1801.	13.7	72
43	Mapping routine measles vaccination in low- and middle-income countries. <i>Nature</i> , 2021, 589, 415-419.	27.8	71
44	Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. <i>Occupational and Environmental Medicine</i> , 2020, 77, 151-159.	2.8	64
45	The Omicron (B.1.1.529) variant of SARS-CoV-2 binds to the hACE2 receptor more strongly and escapes the antibody response: Insights from structural and simulation data. <i>International Journal of Biological Macromolecules</i> , 2022, 200, 438-448.	7.5	64
46	Mapping disparities in education across low- and middle-income countries. <i>Nature</i> , 2020, 577, 235-238.	27.8	58
47	Global and regional burden of chronic respiratory disease in 2016 arising from non-infectious airborne occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016. <i>Occupational and Environmental Medicine</i> , 2020, 77, 142-150.	2.8	56
48	Global and regional burden of disease and injury in 2016 arising from occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016. <i>Occupational and Environmental Medicine</i> , 2020, 77, 133-141.	2.8	56
49	Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 222-241.	9.1	53
50	Interaction of Hepatitis C virus proteins with pattern recognition receptors. <i>Virology Journal</i> , 2012, 9, 126.	3.4	51
51	Prediction of promiscuous T-cell epitopes in the Zika virus polyprotein: An in silico approach. <i>Asian Pacific Journal of Tropical Medicine</i> , 2016, 9, 844-850.	0.8	49
52	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. <i>Nature Medicine</i> , 2020, 26, 750-759.	30.7	47
53	Public health utility of cause of death data: applying empirical algorithms to improve data quality. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 175.	3.0	45
54	Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. <i>Injury Prevention</i> , 2020, 26, i125-i153.	2.4	44

#	ARTICLE	IF	CITATIONS
55	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i12-i26.	2.4	44
56	Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis. <i>Cells</i> , 2021, 10, 1392.	4.1	40
57	Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990â€“2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>Lancet Public Health</i> , The, 2021, 6, e482-e499.	10.0	38
58	Subnational mapping of HIV incidence and mortality among individuals aged 15â€“49 years in sub-Saharan Africa, 2000â€“18: a modelling study. <i>Lancet HIV</i> ,the, 2021, 8, e363-e375.	4.7	32
59	Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Punjab Province in Pakistan and a phylogenetic analysis. <i>International Journal of Infectious Diseases</i> , 2013, 17, e247-e253.	3.3	30
60	Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An In Silico Analysis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-15.	2.2	29
61	Development of Global Consensus Sequence and Analysis of Highly Conserved Domains of HCV NS5B Protein. [10.5812/hepatmon.6142]. <i>Hepatitis Monthly</i> , 2012, 12, e6142.	0.2	28
62	Phylogenetic analysis of torque teno virus genome from Pakistani isolate and incidence of co-infection among HBV/HCV infected patients. <i>Virology Journal</i> , 2012, 9, 320.	3.4	28
63	Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2. <i>Journal of Molecular Modeling</i> , 2021, 27, 206.	1.8	28
64	Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. <i>Infection, Genetics and Evolution</i> , 2011, 11, 640-645.	2.3	27
65	Awareness and risk factors associated with barbers in transmission of hepatitis B and C from Pakistani population: barberâ€™s role in viral transmission. <i>Asian Biomedicine</i> , 2010, 4, 435-442.	0.3	26
66	Hepatitis B and hepatitis C viruses: a review of viral genomes, viral induced host immune responses, genotypic distributions and worldwide epidemiology. <i>Asian Pacific Journal of Tropical Disease</i> , 2014, 4, 88-96.	0.5	25
67	Zika virus, a pathway to new challenges. <i>Asian Pacific Journal of Tropical Medicine</i> , 2016, 9, 626-629.	0.8	25
68	Designing a multi-epitope vaccine against <i>Mycobacteroides abscessus</i> by pangenome-reverse vaccinology. <i>Scientific Reports</i> , 2021, 11, 11197.	3.3	25
69	Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan. <i>Asian Pacific Journal of Tropical Biomedicine</i> , 2012, 2, 532-536.	1.2	24
70	Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000â€“2018. <i>Nature Human Behaviour</i> , 2021, 5, 1027-1045.	12.0	24
71	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000â€“17. <i>The Lancet Global Health</i> , 2020, 8, e1038-e1060.	6.3	23
72	RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs. <i>Infection, Genetics and Evolution</i> , 2013, 14, 247-257.	2.3	22

#	ARTICLE	IF	CITATIONS
73	Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. <i>International Journal of Infectious Diseases</i> , 2012, 16, e597-e602.	3.3	20
74	Estimation of Hepatitis B Virus, Hepatitis C Virus, and Different Clinical Parameters in the Thalassemic Population of Capital Twin Cities of Pakistan. <i>Virology: Research and Treatment</i> , 2015, 6, VRT.S31744.	3.5	18
75	Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme. <i>Molecules</i> , 2021, 26, 1446.	3.8	18
76	Distribution of hepatitis C virus genotypes, hepatic steatosis and their correlation with clinical and virological factors in Pakistan. <i>Asian Biomedicine</i> , 2010, 4, 253-262.	0.3	18
77	Role of Potash Alum in Hepatitis C virus Transmission at Barber's Shop. <i>Virology Journal</i> , 2011, 8, 211.	3.4	16
78	Polio eradication challenges in Pakistan. <i>Clinical Microbiology and Infection</i> , 2018, 24, 6-7.	6.0	16
79	Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: Treatment response, side effects and future prospective. <i>Asian Pacific Journal of Tropical Medicine</i> , 2015, 8, 85-89.	0.8	15
80	A computational study to disclose potential drugs and vaccine ensemble for COVID-19 conundrum. <i>Journal of Molecular Liquids</i> , 2021, 324, 114734.	4.9	15
81	Hepatitis C eradication: A long way to go. <i>World Journal of Gastroenterology</i> , 2015, 21, 12510.	3.3	15
82	Frequency of HEV contamination in sewerage waters in Pakistan. <i>Journal of Infection in Developing Countries</i> , 2010, 4, 842-845.	1.2	15
83	Sequence and Structural Analysis of 3' Untranslated Region of Hepatitis C Virus, Genotype 3a, From Pakistani Isolates. <i>Hepatitis Monthly</i> , 2013, 13, e8390.	0.2	14
84	Transition from millennium development goals to sustainable development goals and hepatitis. <i>Pathogens and Global Health</i> , 2015, 109, 353-353.	2.3	13
85	Elimination of hepatitis from Pakistan by 2030: is it possible?. <i>Hepatoma Research</i> , 2018, 4, 45.	1.5	13
86	Ledipasvir and sofosbuvir: Interferon free therapy for HCV genotype 1 infection. <i>World Journal of Virology</i> , 2015, 4, 33.	2.9	11
87	Epidemiological patterns and risk factors associated with hepatitis B virus in Pakistani population. <i>Asian Biomedicine</i> , 2010, 4, 547-554.	0.3	11
88	Efficacy and Safety of Remdesivir in COVID-19 Positive Dialysis Patients. <i>Antibiotics</i> , 2022, 11, 156.	3.7	11
89	Mutations in the STAT1-interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy. <i>Molecular Medicine Reports</i> , 2013, 8, 487-492.	2.4	10
90	Pakistan needs to speed up its human immunodeficiency virus control strategy to achieve targets in fast-track acquired immune deficiency syndrome response. <i>World Journal of Virology</i> , 2017, 6, 46.	2.9	10

#	ARTICLE	IF	CITATIONS
91	Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach. <i>Journal of Molecular Liquids</i> , 2021, 330, 115636.	4.9	10
92	Identification of novel silent HIV propagation routes in Pakistan. <i>World Journal of Virology</i> , 2013, 2, 136.	2.9	10
93	Design of a Multi-Epitopes Vaccine against Hantaviruses: An Immunoinformatics and Molecular Modelling Approach. <i>Vaccines</i> , 2022, 10, 378.	4.4	10
94	Potential Immunogenic Activity of Computationally Designed mRNA- and Peptide-Based Prophylactic Vaccines against MERS, SARS-CoV, and SARS-CoV-2: A Reverse Vaccinology Approach. <i>Molecules</i> , 2022, 27, 2375.	3.8	10
95	Evaluation of HIV/AIDS diagnostics kits and formulation of a testing strategy for Pakistan. <i>Journal of Clinical Virology</i> , 2013, 56, 367-369.	3.1	9
96	Prediction and conservancy analysis of promiscuous T-cell binding epitopes of Ebola virus L protein: An in silico approach. <i>Asian Pacific Journal of Tropical Disease</i> , 2016, 6, 169-173.	0.5	9
97	Prevalence of hepatitis C in people who inject drugs in the cities of Rawalpindi and Islamabad, Pakistan. <i>Biomedical Reports</i> , 2017, 7, 263-266.	2.0	9
98	Analyses of ABO blood groups with susceptibility and symptomatic variations of COVID-19 infection, a questionnaire-based survey. <i>Apmis</i> , 2021, 129, 579-586.	2.0	9
99	Ebola in West Africa: an international medical emergency. <i>Asian Pacific Journal of Tropical Biomedicine</i> , 2014, 4, 673-674.	1.2	8
100	Sequence analysis of the L protein of the Ebola 2014 outbreak: Insight into conserved regions and mutations. <i>Molecular Medicine Reports</i> , 2016, 13, 4821-4826.	2.4	8
101	Prediction of promiscuous T cell epitopes in RNA dependent RNA polymerase of Chikungunya virus. <i>Asian Pacific Journal of Tropical Medicine</i> , 2017, 10, 760-764.	0.8	8
102	Modern biotechnology-based therapeutic approaches against HIV infection (Review). <i>Biomedical Reports</i> , 2017, 7, 504-507.	2.0	8
103	Prognostic Role of Monocytic Myeloid-Derived Suppressor Cells in Advanced Non-Small-Cell Lung Cancer: Relation to Different Hematologic Indices. <i>Journal of Immunology Research</i> , 2021, 2021, 1-10.	2.2	8
104	Beneficial Effects of Anticoagulants on the Clinical Outcomes of COVID-19 Patients. <i>Antibiotics</i> , 2021, 10, 1394.	3.7	8
105	The interplay between vitamin D and COVID-19: protective or bystander?. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 2131-2145.	0.7	8
106	Comparison of Low-Versus High-Dose Steroids in the Clinical Outcome of Hospitalized COVID-19 Patients. <i>Antibiotics</i> , 2021, 10, 1510.	3.7	8
107	Evaluation of the Whole Proteome of <i>Achromobacter xylosoxidans</i> to Identify Vaccine Targets for mRNA and Peptides-Based Vaccine Designing Against the Emerging Respiratory and Lung Cancer-Causing Bacteria. <i>Frontiers in Medicine</i> , 2021, 8, 825876.	2.6	7
108	Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population. <i>Chinese Medical Journal</i> , 2011, 124, 1333-7.	2.3	7

#	ARTICLE	IF	CITATIONS
109	Progress on global hepatitis elimination targets. <i>World Journal of Gastroenterology</i> , 2021, 27, 8199-8200.	3.3	7
110	Islam and polio. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 791-792.	9.1	6
111	The World after Ebola: An Overview of Ebola Complications, Vaccine Development, Lessons Learned, Financial Losses, and Disease Preparedness. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2019, 29, 77-84.	0.9	6
112	Familial clustering of hepatitis C virus in a Pakistani population. <i>Journal of Medical Virology</i> , 2020, 92, 3499-3506.	5.0	6
113	Evaluation of Three Rapid Screening Tests for Detection of Hepatitis C Antibodies on Mass Scale. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2019, 29, 25-28.	0.9	5
114	Role of Therapeutic Plasmapheresis in SARS-CoV-2 Induced Cytokine Release Syndrome: A Retrospective Cohort Study on COVID-19 Patients. <i>International Journal of General Medicine</i> , 2022, Volume 15, 4907-4916.	1.8	5
115	Sequence analysis of hepatitis C virus nonstructural protein 3 ^{â€} 4A serine protease and prediction of conserved B and T cell epitopes. <i>Biomedical Reports</i> , 2017, 7, 563-566.	2.0	4
116	Clinical outcomes of moderate to severe COVID-19 patients receiving invasive vs. non-invasive ventilation. <i>Asian Pacific Journal of Tropical Medicine</i> , 2021, 14, 176.	0.8	4
117	Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study. <i>PeerJ</i> , 2018, 6, e4853.	2.0	4
118	Computational Evaluation of Abrogation of HBx-Bcl-xL Complex with High-Affinity Carbon Nanotubes (Fullerene) to Halt the Hepatitis B Virus Replication. <i>Molecules</i> , 2021, 26, 6433.	3.8	4
119	Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. <i>Viral Immunology</i> , 2018, 31, 632-638.	1.3	3
120	Possible Role of Regulatory B Cells in Different Beh ^Å set ^{â€} ™s Disease Phenotypes and Therapies: First Report from Egypt. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 737-744.	3.5	3
121	Burden of Transport-Related Injuries in the Eastern Mediterranean Region: A Systematic Analysis for the Global Burden of Disease Study 2017. <i>Archives of Iranian Medicine</i> , 2021, 24, 512-525.	0.6	2
122	In silico identification of BIM-1 (2-methyl-1H-indol-3-yl) as a potential therapeutic agent against elevated protein kinase C beta associated diseases. <i>African Journal of Biotechnology</i> , 2012, 11, .	0.6	2
123	Correlation of Apolipoprotein B mRNA-editing Enzyme, Catalytic Polypeptide- like 3G Genetic Variant rs8177832 with HIV-1 Predisposition in Pakistani Population. <i>Current HIV Research</i> , 2019, 16, 297-301.	0.5	2
124	Annotation of Potential Vaccine Targets and Design of a Multi-Epitope Subunit Vaccine against <i>Yersinia pestis</i> through Reverse Vaccinology and Validation through an Agent-Based Modeling Approach. <i>Vaccines</i> , 2021, 9, 1327.	4.4	2
125	Immunoinformatic Approach to Contrive a Next Generation Multi-Epitope Vaccine Against <i>Achromobacter xylosoxidans</i> Infections. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2
126	Sequence comparison and phylogenetic analysis of Hepatitis C virus genotype 3 polymerase. <i>Molecular Medicine Reports</i> , 2014, 9, 1266-1270.	2.4	1

#	ARTICLE	IF	CITATIONS
127	Recent advances on Ebola virus. Asian Pacific Journal of Tropical Disease, 2017, 7, 65-67.	0.5	1
128	Prediction of promiscuous epitopes in NSP2 of Chikungunya virus: An in-silico approach. Tropical Biomedicine, 2020, 37, 566-577.	0.7	1
129	An in silico study to unveil potential drugs and vaccine chimera for HBV capsid assembly protein: combined molecular docking and dynamics simulation approach. Journal of Molecular Modeling, 2022, 28, 51.	1.8	1
130	Mapping the effect of drugs on ACE2 as a novel target site for COVID-19 therapy. European Review for Medical and Pharmacological Sciences, 2021, 25, 3923-3932.	0.7	1
131	SARS-CoV-2 associated pathogenesis, immune dysfunction and involvement of host factors: a comprehensive review.. European Review for Medical and Pharmacological Sciences, 2021, 25, 7526-7542.	0.7	1
132	Scavenger receptor class-A plays diverse role in innate immunity, cell signaling and different pathologies. Asian Pacific Journal of Tropical Disease, 2016, 6, 567-572.	0.5	0
133	Risk of Malignancy in Breast FNAB Categories, Classified According to the Newly Proposed International Academy of Cytology (IAC) Yokohama System. Cancer Management and Research, 2022, Volume 14, 1693-1701.	1.9	0